Evidence map›Paper›PMID 39333608›Full record

ArticleScientific reports2024

Developing machine learning models for personalized treatment strategies in early breast cancer patients undergoing neoadjuvant systemic therapy based on SEER database.

Jiahui Ren, Yili Li, Jing Zhou, Ting Yang, Jingfeng Jing, Qian Xiao, Zhongxu Duan, Ke Xiang, Yuchen Zhuang, Daxue Li and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Applications of Artificial Intelligence (AI) in Breast Cancer Care Delivery and Education: A Scoping Review.International journal of environmental research and public health · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiahui RenBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Yili LiBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Jing ZhouBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Ting YangBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Jingfeng JingBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Qian XiaoBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Zhongxu DuanBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Ke XiangBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Yuchen ZhuangBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China.
Daxue LiBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China. ldx_8793@hotmail.com.
Han GaoBreast and Thyroid Surgery Department, Chongqing Health Center for Women and Children, Chongqing, China. 15223323120@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to compare the long-term outcomes of breast-conserving surgery plus radiotherapy (BCS + RT) and mastectomy in early breast cancer (EBC) patients who received neoadjuvant systemic therapy (NST), and sought to construct and authenticate a machine learning algorithm that could assist healthcare professionals in formulating personalized treatment strategies for this patient population. We analyzed data from the Surveillance, Epidemiology, and End Results database on EBC patients undergoing BCS + RT or mastectomy post-NST (2010-2018). Employing propensity score matching (PSM) to minimize potential biases, we compared breast cancer-specific survival (BCSS) and overall survival (OS) between the two surgical groups. Additionally, we trained and validated six machine learning survival models and developed a cloud-based recommendation system for surgical treatment based on the optimal model. Among the 13,958 patients, 9028 (64.7%) underwent BCS + RT and 4930 (35.3%) underwent mastectomy. After PSM, there were 3715 patients in each group. Compared to mastectomy, BCS + RT significantly improved BCSS (p < 0.001) and OS (p < 0.001). Prognostic variables associated with BCSS were utilized to develop machine learning models. In both the training and validation cohorts, the random survival forest (RSF) model demonstrated superior predictive performance (0.847 and 0.795), not only outperforming other machine learning models, including Rpart (0.725 and 0.707), Xgboost (0.762 and 0.727), Glmboost (0.748 and 0.788), Survctree (0.764 and 0.766), and Survsvm (0.777 and 0.790), but also outperforming the classical COX model (0.749 and 0.782). Lastly, a web-based prediction tool was built to facilitate clinical application [ https://jhren.shinyapps.io/shinyapp1 ]. After adjusting other confounders, BCS + RT was associated with improved outcomes in patients with EBC after NST, compared to those who underwent mastectomy. Moreover, the RSF model, a reliable tool, can predict long-term outcomes for patients, providing valuable guidance for operative methods and postoperative follow-up.

Indexed as

Breast NeoplasmsMachine LearningMastectomyNeoadjuvant TherapyPrecision MedicineSEER ProgramAdultAgedFemaleHumansMastectomy, SegmentalMiddle AgedPrognosisBreast-conserving surgeryEarly breast cancerLong-term outcomesMachine learningMastectomyNeoadjuvant systemic therapy

Identifiers

PMID39333608
PMCPMC11436944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.